Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by AC Immune SA AC Immune Receives Second Milestone Payment Following Progress in Phase 2b ReTain Trial of ACI-35.030 in Preclinical Alzheimer’s Disease September 17, 2024 From AC Immune SA Via GlobeNewswire Tickers ACIU AC Immune’s PI-2620 Tau-PET Diagnostic in Phase 3 Receives Fast Track Designation in Three Neurodegenerative Conditions August 28, 2024 From AC Immune SA Via GlobeNewswire Tickers ACIU AC Immune Reports Second Quarter 2024 Financial Results and Provides a Corporate Update August 06, 2024 From AC Immune SA Via GlobeNewswire Tickers ACIU AC Immune Unveils Novel Therapeutic Antibody Drug Conjugate (ADC) Technology for Improved Efficacy in Neurodegenerative Diseases at AAIC 2024 July 31, 2024 From AC Immune SA Via GlobeNewswire Tickers ACIU AC Immune’s ACI-35.030 (now “JNJ-2056”) Granted FDA Fast Track Designation for Alzheimer’s Disease July 25, 2024 From AC Immune SA Via GlobeNewswire Tickers ACIU AC Immune Showcasing its Novel Morphomer-Antibody Drug Conjugate (morADC) Platform for the Treatment of Neurodegenerative Diseases at AAIC 2024 July 16, 2024 From AC Immune SA Via GlobeNewswire Tickers ACIU AC Immune to Present at the Jefferies Global Healthcare Conference in June 2024 May 28, 2024 From AC Immune SA Via GlobeNewswire Tickers ACIU AC Immune Reports First Quarter 2024 Financial Results and Provides a Corporate Update May 13, 2024 From AC Immune SA Via GlobeNewswire Tickers ACIU AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer’s Disease May 13, 2024 From AC Immune SA Via GlobeNewswire Tickers ACIU AC Immune Reports Full Year 2023 Financial Results and Provides a Corporate Update March 14, 2024 From AC Immune SA Via GlobeNewswire Tickers ACIU AC Immune Announces Upcoming Presentations at AD/PD™ 2024 February 22, 2024 From AC Immune SA Via GlobeNewswire Tickers ACIU AC Immune to Regain Global Rights to Crenezumab and Semorinemab January 22, 2024 From AC Immune SA Via GlobeNewswire Tickers ACIU AC Immune Progress Update on Phase 2 Active Immunotherapy Clinical Pipeline for Alzheimer's and Parkinson diseases January 03, 2024 From AC Immune SA Via GlobeNewswire Tickers ACIU AC Immune Announces Pricing of Underwritten Offering of Common Shares December 15, 2023 From AC Immune SA Via GlobeNewswire Tickers ACIU AC Immune’s Targeted Anti-pTau Active Immunotherapy for Alzheimer’s Disease Advances into Phase 2b Trial December 15, 2023 From AC Immune SA Via GlobeNewswire Tickers ACIU AC Immune Strengthens Management, Appoints Madiha Derouazi as CSO and Christopher Roberts as CFO December 01, 2023 From AC Immune SA Via GlobeNewswire Tickers ACIU AC Immune to Present at the Jefferies 2023 London Healthcare Conference November 07, 2023 From AC Immune SA Via GlobeNewswire Tickers ACIU AC Immune Reports Third Quarter 2023 Financial Results and Provides a Corporate Update November 03, 2023 From AC Immune SA Via GlobeNewswire Tickers ACIU AC Immune to Host KOL Webinar on Amyloid Plaque PET Imaging in Alzheimer’s Disease as a Surrogate of Clinical Efficacy on November 9, 2023 November 02, 2023 From AC Immune SA Via GlobeNewswire Tickers ACIU AC Immune Clinical Data Published in Nature Communications Show Alpha-Synuclein PET Tracer ACI-12589 Has Potential as Neurodegenerative Disease Diagnostic October 27, 2023 From AC Immune SA Via GlobeNewswire Tickers ACIU AC Immune Announces Upcoming Presentations at the 16th CTAD Conference October 17, 2023 From AC Immune SA Via GlobeNewswire Tickers ACIU AC Immune to Present at the Jefferies 2023 CNS & Neuro Summit in October 2023 October 05, 2023 From AC Immune SA Via GlobeNewswire Tickers ACIU AC Immune to Present at the H.C. Wainwright 25th Annual Global Investment Conference in September 2023 September 05, 2023 From AC Immune SA Via GlobeNewswire Tickers ACIU AC Immune Reports Second Quarter 2023 Financial Results and Provides a Corporate Update August 04, 2023 From AC Immune SA Via GlobeNewswire Tickers ACIU AC Immune to Present at the BTIG Virtual Biotechnology Conference 2023 July 28, 2023 From AC Immune SA Via GlobeNewswire Tickers ACIU AC Immune SA Appoints New Chief Medical Officer July 26, 2023 From AC Immune SA Via GlobeNewswire Tickers ACIU AC Immune Showcasing Precision Medicine Programs at AAIC 2023 July 03, 2023 From AC Immune SA Via GlobeNewswire Tickers ACIU AC Immune Receives FDA Fast Track Designation for Anti-Amyloid-beta Active Immunotherapy, ACI-24.060, to Treat Alzheimer’s Disease June 27, 2023 From AC Immune SA Via GlobeNewswire Tickers ACIU AC Immune Holds Annual General Meeting of Shareholders June 23, 2023 From AC Immune SA Via GlobeNewswire Tickers ACIU AC Immune Reports First Quarter 2023 Financial Results and Provides a Corporate Update April 28, 2023 From AC Immune SA Via GlobeNewswire Tickers ACIU Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.